泛福舒治疗肺源性心脏病的疗效观察

Effect of Brocho-Vaxom in curing chronic pulmonary heart disease

目的探讨泛福舒治疗慢性肺源性心脏病(肺心病)的疗效及对患者免疫功能的影响。方法肺心病患者58例,随机分为泛福舒组和对照组各29例。泛福舒组每日早晨空腹口服泛福舒,观察治疗后呼吸道感染次数、持续时间。快速免疫比浊法测定治疗前后血清免疫球蛋白IgA、IgG、IgM含量,SP一步法测定淋巴细胞亚群,四甲基偶氮唑盐比色法(MTT)法测定NK细胞活性。结果泛福舒组感染次数减少,5个月平均为(2.5±1.8)次,对照组为(3.6±2.9)次(P<0.01);感染持续时间泛福舒组5个月平均为(7.9±6.3)d,对照组为(10.8±8.4)d,泛福舒组比对照组明显缩短(P<0.01);泛福舒组治疗前后IgA、IgG含量水平差异有统计学意义,而对照组均无变化;泛福舒组治疗后CD4+、CD4+/CD8+、NK升高(P<0.05),CD8+明显下降(P<0.01),对照组治疗前后CD4+、CD8+、CD4+/CD8+、NK均无明显变化。结论泛福舒能提高患者免疫功能,对肺心病患者有较好的疗效。

Objective To investigate the effect of Brocho-Vaxom in curing chronic pulmonary heart disease and the influence of patient＇s immunity. Methods 58 patients with chronic pulmonary heart disease were randomly divided into two equal groups. Each patient of treatment group took a Brocho-Vaxom eapsule（7mg/cap） every. The respiratory tract infection times and duration were observed. The serum IgA, IgG, IgM level were tested by fast immunonephelometry. The sub-type lymphocyte was tested by SP,and the NK cell＇s activity was tested by MTT. Resuits The infection time obviously declined in treatment group which the average was （2.5 ± 1.8） in five months as compared with that in the controlled group（P〈 0.01 ） ,which the average was （3.6± 2.9） in five months. And the duration in the treatment group was also reduced（ P 〈 0.01 ）. The infective duration in treatment group was （7.9 ± 6.3 ） days, while it was （ 10.8 ± 8.4 ） days in the controlled group. The average level of IgA, IgG were risen in the treatment group（ P 〈 0.01 ）, and the other didn＇ t change. CD4^＋ , CD4^＋/CD8^＋ , NK were risen in the treatment group（P 〈 0.05）, CD8^＋ was reduced（ P 〈 0.01 ）, and there was no change in the treatment group. Conclusion There are good effects in treated chronic pulmonary heart disease with Brocho-Vaxom which can improve the patient＇ s immunity.